One cell therapy to treat them all – or at least 120-plus different diseases. Garuda Therapeutics closed a $62 million Series B round Tuesday to support its off-the-shelf, self-renewing blood stem cell technology.
Using a patient’s own depleted cells or seeking out a biological donor match is both costly and time prohibitive. Garuda’s proprietary hematopoietic stem cells could be the industry’s first off-the-shelf offering, leading to faster, more effective treatments and greater patient accessibility. read more →